Prognostic factors for clinical response of alopecia areata to topical immunotherapy with squaric acid dibutylester

Arch Dermatol. 1997 Apr;133(4):539-40. doi: 10.1001/archderm.133.4.539.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Administration, Topical
  • Adolescent
  • Adult
  • Alopecia Areata / drug therapy*
  • Child
  • Cyclobutanes / administration & dosage*
  • Female
  • Humans
  • Immunotherapy
  • Male
  • Middle Aged
  • Prognosis

Substances

  • Cyclobutanes
  • squaric acid dibutyl ester